Skip to main content
Fig. 5 | BMC Medicine

Fig. 5

From: Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status

Fig. 5

HER2-low breast tumor had different clinical outcomes than HER2-zero. A HER2-low subgroup had lower pathological complete response (pCR) rates. B Proportion of relapsed/progressed patients were fewer in HER2-low subgroup across follow-up time points. The table below summarizes the number of relapsed patients over the total number of included patients per time point (in year) per subgroup. The gray connecting lines in the box plot denote the follow-up data per year corresponding to the data point in the dot plot on the left

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us